The biotech firm reported RMB11.8 billion in revenue for 1H, with adjusted gross margins rising to 46.2%.
Wuxi Biologics ADR (WXXWY) reported first-half revenue of RMB11.8 billion, up 18.4% year-over-year, or 23.4% in USD terms. Non-GAAP earnings per share reached RMB0.81 for the period.
The company’s IFRS gross profit margin improved to 46.2%, a 350-basis-point increase from the prior year. Adjusted gross margins also expanded, though specific figures were not detailed in the release.
No immediate market reaction was disclosed in the announcement.